Mechanism, consequences, and therapeutic targeting of abnormal IL15 signaling in cutaneous T-cell lymphoma

Cancer Discovery

Volumn 6, Issue 9, 2016, Pages 986-1005

  Mishra, Anjali ^a,b   La Perle, Krista ^a,b   Kwiatkowski, Sonya ^b   Sullivan, Laura A ^b   Sams, Gregory H ^b   Johns, Jessica ^b   Curphey, Douglas P ^b   Wen, Jing ^b   McConnell, Kathleen ^b   Qi, Jun ^c   Wong, Henry ^a,b   Russo, Giandomenico ^d   Zhang, Jianying ^a   Marcucci, Guido ^e   Bradner, James E ^c   Porcu, Pierluigi ^a,b   Caligiuri, Michael A ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^e CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 6; INTERLEUKIN 15; LUCIFERASE; MICRORNA 21; TRANSCRIPTION FACTOR ZEB1; HDAC1 PROTEIN, HUMAN; HDAC6 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IL15 PROTEIN, HUMAN; MICRORNA; MIRN21 MICRORNA, HUMAN; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; ZEB1 PROTEIN, HUMAN;

ANIMAL MODEL; ARTICLE; CANCER GROWTH; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL VIABILITY ASSAY; CONTROLLED STUDY; CPG ISLAND; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; ENZYME ACTIVITY; EPIGENETICS; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LUCIFERASE ASSAY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; LYMPHOMA, T-CELL, CUTANEOUS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; INFLAMMATION; INTERLEUKIN-15; LYMPHOMA, T-CELL, CUTANEOUS; MICE; MICRORNAS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 85012040971     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-1297     Document Type: Article

References (87)

1. Willemze R., Jaffe ES., Burg G., Cerroni L., Berti E., Swerdlow SH., et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-85.
2. Olsen E., Vonderheid E., Pimpinelli N., Willemze R., Kim Y., Knobler R., et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110: 1713-22.
3. Duvic M., Talpur R., Ni X., Zhang C., Hazarika P., Kelly C., et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007; 109: 31-9.
4. Whittaker SJ., Demierre MF., Kim EJ., Rook AH., Lerner A., Duvic M., et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28: 4485-91.
5. Yamanaka K., Clark R., Rich B., Dowgiert R., Hirahara K., Hurwitz D., et al. Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 2006; 107: 2440-5.
6. Singer EM., Shin DB., Nattkemper LA., Benoit BM., Klein RS., Didigu CA., et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol 2013; 133: 2783-5.
7. Krejsgaard T., Litvinov IV., Wang Y., Xia L., Willerslev-Olsen A., Koralov SB., et al. Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma. Blood 2013; 122: 943-50.
8. Guenova E., Watanabe R., Teague JE., Desimone JA., Jiang Y., Dowlatshahi M., et al. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clin Cancer Res 2013; 19: 3755-63.
9. Geskin LJ., Viragova S., Stolz DB., Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood 2015; 125: 2798-805.
10. Asadullah K., Haeussler-Quade A., Gellrich S., Hanneken S., Hansen-Hagge TE., Docke WD., et al. IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: Stage-dependent increase in mycosis fungoides progression. Exp Dermatol 2000; 9: 248-51.
11. Wasik MA. IL-13 as a novel growth factor in CTCL. Blood 2015; 125: 2737-8.
12. Vowels BR., Lessin SR., Cassin M., Jaworsky C., Benoit B., Wolfe JT., et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994; 103: 669-73.
13. Krejsgaard T., Ralfkiaer U., Clasen-Linde E., Eriksen KW., Kopp KL., Bonefeld CM., et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the Jak3/Stat3 signaling pathway. J Invest Dermatol 2011; 131: 1331-8.
14. Dobbeling U., Dummer R., Laine E., Potoczna N., Qin JZ., Burg G. Interleukin-15 is an autocrine/paracrine viability factor for cutaneous T-cell lymphoma cells. Blood 1998; 92: 252-8.
15. Mishra A., Sullivan L., Caligiuri MA. Molecular pathways: Interleukin-15 signaling in health and in cancer. Clin Cancer Res 2014; 20: 2044-50.
16. Fehniger TA., Caligiuri MA. Interleukin 15: Biology and relevance to human disease. Blood 2001; 97: 14-32.
17. Leroy S., Dubois S., Tenaud I., Chebassier N., Godard A., Jacques Y., et al. Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Dermatol 2001; 144: 1016-23.
18. Marzec M., Halasa K., Kasprzycka M., Wysocka M., Liu X., Tobias JW., et al. Differential effects of interleukin-2 and interleukin-15 versus interleukin-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res 2008; 68: 1083-91.
19. Qin JZ., Zhang CL., Kamarashev J., Dummer R., Burg G., Dobbeling U. Interleukin-7 and interleukin-15 regulate the expression of the bcl-2 and c-myb genes in cutaneous T-cell lymphoma cells. Blood 2001; 98: 2778-83.
20. Han GW., Iwatsuki K., Inoue M., Matsui T., Nishibu A., Akiba H., et al. Interleukin-15 is not a constitutive cytokine in the epidermis, but is inducible in culture or infl ammatory conditions. Acta Derm Venereol 1999; 79: 37-40.
21. Marzec M., Liu X., Kasprzycka M., Witkiewicz A., Raghunath PN., El-Salem M., et al. IL-2-and IL-15-induced activation of the rapamycinsensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood 2008; 111: 2181-9.
22. Kasprzycka M., Zhang Q., Witkiewicz A., Marzec M., Potoczek M., Liu X., et al. Gamma c-signaling cytokines induce a regulatory T cell phenotype in malignant CD4+ T lymphocytes. J Immunol 2008; 181: 2506-12.
23. Adachi T., Kobayashi T., Sugihara E., Yamada T., Ikuta K., Pittaluga S., et al. Hair follicle-derived IL-7 and IL-15 mediate skin-resident memory T cell homeostasis and lymphoma. Nat Med 2015; 21: 1272-9.
24. Wang J., Lee S., Teh CE., Bunting K., Ma L., Shannon MF. T he transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells. Int Immunol 2009; 21: 227-35.
25. Sanchez-Tillo E., de Barrios O., Siles L., Amendola PG., Darling DS., Cuatrecasas M., et al. ZEB1 Promotes invasiveness of colorectal carcinoma cells through the opposing regulation of uPA and PAI-1. Clin Cancer Res 2013; 19: 1071-82.
26. Fehniger TA., Suzuki K., Ponnappan A., VanDeusen JB., Cooper MA., Florea SM., et al. Fatal leukemia in interleukin 15 transgenic mice follows early expansions in natural killer and memory phenotype CD8+ T cells. J Exp Med 2001; 193: 219-31.
27. Mishra A., Liu S., Sams GH., Curphey DP., Santhanam R., Rush LJ., et al. Aberrant overexpression of IL-15 initiates large granular lymphocyte leukemia through chromosomal instability and DNA hypermethylation. Cancer Cell 2012; 22: 645-55.
28. Edelson RL. Cutaneous T cell lymphoma: The helping hand of dendritic cells. Ann N Y Acad Sci 2001; 941: 1-11.
29. Cornejo MG., Kharas MG., Werneck MB., Le Bras S., Moore SA., Ball B., et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models. Blood 2009; 113: 2746-54.
30. Whittaker S. Biological insights into the pathogenesis of cutaneous T-cell lymphomas (CTCL). Semin Oncol 2006; 33 (1 Suppl 3): S3-6.
31. Borowitz MJ., Weidner A., Olsen EA., Picker LJ. Abnormalities of circulating T-cell subpopulations in patients with cutaneous T-cell lymphoma: cutaneous lymphocyte-associated antigen expression on T cells correlates with extent of disease. Leukemia 1993; 7: 859-63.
32. O’Connor OA., Toner LE., Vrhovac R., Budak-Alpdogan T., Smith EA., Bergman P. Comparative animal models for the study of lymphohematopoietic tumors: Strengths and limitations of present approaches. Leuk Lymphoma 2005; 46: 973-92.
33. Weinberg JM., Jaworsky C., Benoit BM., Telegan B., Rook AH., Lessin SR. The clonal nature of circulating Sezary cells. Blood 1995; 86: 4257-62.
34. Rangwala S., Zhang C., Duvic M. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas. Future Med Chem 2012; 4: 471-86.
35. Schuettengruber B., Simboeck E., Khier H., Seiser C. Autoregulation of mouse histone deacetylase 1 expression. Mol Cell Biol 2003; 23: 6993-7004.
36. Johnstone RW., Licht JD. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell 2003; 4: 13-8.
37. Wilting RH., Yanover E., Heideman MR., Jacobs H., Horner J., van der Torre J., et al. Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. EMBO J 2010; 29: 2586-97.
38. Cabrero JR., Serrador JM., Barreiro O., Mittelbrunn M., Naranjo-Suarez S., Martin-Cofreces N., et al. Lymphocyte chemotaxis is regulated by histone deacetylase 6, independently of its deacetylase activity. Mol Biol Cell 2006; 17: 3435-45.
39. Creyghton MP., Cheng AW., Welstead GG., Kooistra T., Carey BW., Steine EJ., et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A 2010; 107: 21931-6.
40. Hsu PY., Hsu HK., Lan X., Juan L., Yan PS., Labanowska J., e t al. Amplifi-cation of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. Cancer Cell 2013; 24: 197-212.
41. Medina PP., Nolde M., Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 2010; 467: 86-90.
42. Narducci MG., Arcelli D., Picchio MC., Lazzeri C., Pagani E., Sampogna F., et al. MicroRNA profiling reveals that miR-21, miR486 and miR-214 are upregulated and involved in cell survival in Sezary syndrome. Cell Death Dis 2011; 2: e151.
43. Sandoval J., Diaz-Lagares A., Salgado R., Servitje O., Climent F., Ortiz-Romero PL., et al. MicroRNA expression profiling and DNA methylation signature for deregulated microRNA in cutaneous T-cell lymphoma. J Invest Dermatol 2015; 135: 1128-37.
44. van der Fits L., van Kester MS., Qin Y., Out-Luiting JJ., Smit F., Zoutman WH., et al. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sezary syndrome. J Invest Dermatol 2011; 131: 762-8.
45. Batty N., Malouf GG., Issa JP. Histone deacetylase inhibitors as antineoplastic agents. Cancer Lett 2009; 280: 192-200.
46. Methot JL., Chakravarty PK., Chenard M., Close J., Cruz JC., Dahlberg WK., et al. Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2). Bioorg Med Chem Lett 2008; 18: 973-8.
47. Guan JS., Haggarty SJ., Giacometti E., Dannenberg JH., Joseph N., Gao J., et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 2009; 459: 55-60.
48. Malamut G., El Machhour R., Montcuquet N., Martin-Lanneree S., Dusanter-Fourt I., Verkarre V., et al. IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated infl ammation and lymphomagenesis. J Clin Invest 2010; 120: 2131-43.
49. Wu S., Fischer L., Gokbuget N., Schwartz S., Burmeister T., Notter M., et al. Expression of interleukin 15 in primary adult acute lymphoblastic leukemia. Cancer 2010; 116: 387-92.
50. Gazdar AF., Carney DN., Bunn PA., Russell EK., Jaffe ES., Schechter GP., et al. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 1980; 55: 409-17.
51. Poiesz BJ., Ruscetti FW., Gazdar AF., Bunn PA., Minna JD., Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980; 77: 7415-9.
52. Bamford RN., Battiata AP., Burton JD., Sharma H., Waldmann TA. Interleukin (IL) 15/IL-T production by the adult T-cell leukemia cell line HuT-102 is associated with a human T-cell lymphotrophic virus type I region/IL-15 fusion message that lacks many upstream AUGs that normally attenuates IL-15 mRNA translation. Proc Natl Acad Sci U S A 1996; 93: 2897-902.
53. Das PM., Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22: 4632-42.
54. Lewis J., Bird A. DNA methylation and chromatin structure. FEBS Lett 1991; 285: 155-9.
55. van Doorn R., Zoutman WH., Dijkman R., de Menezes RX., Commandeur S., Mulder AA., et al. Epigenetic profiling of cutaneous T-cell lymphoma: Promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005; 23: 3886-96.
56. Contassot E., French LE. Epigenetic causes of apoptosis resistance in cutaneous T-cell lymphomas. J Invest Dermatol 2010; 130: 922-4.
57. Bahar Halpern K., Vana T., Walker MD. Paradoxical role of DNA methylation in activation of FoxA2 gene expression during endoderm development. J Biol Chem 2014; 289: 23882-92.
58. Pipaon C., Real PJ., Fernandez-Luna JL. Defective binding of transcriptional repressor ZEB via DNA methylation contributes to increased constitutive levels of p73 in Fanconi anemia cells. FEBS Lett 2005; 579: 4610-4.
59. de Wilde J., Kooter JM., Overmeer RM., Claassen-Kramer D., Meijer CJ., Snijders PJ., et al. hTERT promoter activity and CpG methylation in HPV-induced carcinogenesis. BMC Cancer 2010; 10: 271.
60. Rojas-Marquez C., Valle-Rios R., Lopez-Bayghen E., Ortiz-Navarrete V. CRTAM is negatively regulated by ZEB1 in T cells. Mol Immunol 2015; 66: 290-8.
61. Choi J., Goh G., Walradt T., Hong BS., Bunick CG., Chen K., et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet 2015; 47: 1011-9.
62. Vermeer MH., van Doorn R., Dijkman R., Mao X., Whittaker S., van Voorst Vader PC., et al. Novel and highly recurrent chromosomal alterations in Sezary syndrome. Cancer Res 2008; 68: 2689-98.
63. Williams TM., Moolten D., Burlein J., Romano J., Bhaerman R., Godillot A., et al. Identification of a zinc finger protein that inhibits IL-2 gene expression. Science 1991; 254: 1791-4.
64. Hidaka T., Nakahata S., Hatakeyama K., Hamasaki M., Yamashita K., Kohno T., et al. Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma. Blood 2008; 112: 383-93.
65. Fedele M., Pentimalli F., Baldassarre G., Battista S., Klein-Szanto AJ., Kenyon L., et al. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 2005; 24: 3427-35.
66. Ponti R., Quaglino P., Novelli M., Fierro MT., Comessatti A., Peroni A., et al. T-cell receptor gamma gene rearrangement by multiplex polymerase chain reaction/heteroduplex analysis in patients with cutaneous T-cell lymphoma (mycosis fungoides/Sezary syndrome) and benign infl ammatory disease: correlation with clinical, histological and immunophenotypical findings. Br J Dermatol 2005; 153: 565-73.
67. Hoppe RT., Medeiros LJ., Warnke RA., Wood GS. CD8-positive tumorinfiltrating lymphocytes infl uence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995; 32: 448-53.
68. Vermeer MH., van Doorn R., Dukers D., Bekkenk MW., Meijer CJ., Willemze R. CD8+ T cells in cutaneous T-cell lymphoma: Expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001; 19: 4322-9.
69. Glozak MA., Seto E. Histone deacetylases and cancer. Oncogene 2007; 26: 5420-32.
70. Kelly Richard DW., Cowley Shaun M. The physiological roles of histone deacetylase (HDAC) 1 and 2: Complex co-stars with multiple leading parts. Biochem Soc Trans 2013; 41: 741-9.
71. West AC., Johnstone RW. New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014; 124: 30-9.
72. Arora A., Gera S., Maheshwari T., Raghav D., Alam MJ., Singh RK., et al. The dynamics of stress p53-Mdm2 network regulated by p300 and HDAC1. PLoS One 2013; 8: e52736.
73. Ito A., Kawaguchi Y., Lai CH., Kovacs JJ., Higashimoto Y., Appella E., et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002; 21: 6236-45.
74. Zhang C., Richon V., Ni X., Talpur R., Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. J Invest Dermatol 2005; 125: 1045-52.
75. Marquard L., Gjerdrum LM., Christensen IJ., Jensen PB., Sehested M., Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008; 53: 267-77.
76. Jenuwein T., Allis CD. Translating the histone code. Science 2001; 293: 1074-80.
77. Gu W., Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.
78. Leoni F., Zaliani A., Bertolini G., Porro G., Pagani P., Pozzi P., et al. The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinfl ammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A 2002; 99: 2995-3000.
79. Villagra A., Sotomayor EM., Seto E. Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 2010; 29: 157-73.
80. Laugesen A., Helin K. Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell 2014; 14: 735-51.
81. Kelly RD., Cowley SM. The physiological roles of histone deacetylase (HDAC) 1 and 2: Complex co-stars with multiple leading parts. Biochem Soc Trans 2013; 41: 741-9.
82. Witt O., Deubzer HE., Milde T., Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009; 277: 8-21.
83. Olsen EA., Kim YH., Kuzel TM., Pacheco TR., Foss FM., Parker S., et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-15.
84. Piekarz RL., Frye R., Turner M., Wright JJ., Allen SL., Kirschbaum MH., et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009; 27: 5410-7.
85. Singh BN., Zhou H., Li J., Tipton T., Wang B., Shao G., et al. Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers. Future Oncol 2011; 7: 1415-28.
86. Suzuki H., Gabrielson E., Chen W., Anbazhagan R., van Engeland M., Weijenberg MP., et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31: 141-9.
87. Thurn KT., Thomas S., Moore A., Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol 2011; 7: 263-83.